AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02212457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenABCWY
Description: Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
Study NCT04440696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Polystyrene Sulphonate Powder
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study NCT04440696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate 500 MG
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study NCT04440696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: D1 was administered once; D2-D12 was administered three times a day; D13 was administered once；
Study NCT03414034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Onvansertib orally
Study NCT03414034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone orally
Study NCT03414034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone orally
Study NCT04629170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration
Study NCT04629170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB8802
Description: SYNB8802 is formulated as a nonsterile solution intended for oral administration
Study NCT04629170 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
Study NCT04629170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder
Study NCT02275754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PN+LCNC
Description: Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
Study NCT02275754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PN Only
Description: Participants will be navigated by PN on request
Study NCT01591915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
Study NCT00743860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: experimental drug
Study NCT02141048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Parenting Skills Training
Description: This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
Study NCT03930849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS
Description: Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
Study NCT03930849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIMS plus
Description: Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
Study NCT00239824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training of the pelvic floor muscles
Description: Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist.
Study NCT00239824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist
Study NCT00239824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist
Study NCT02398734 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sonolysis
Description: Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
Study NCT02398734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sonolysis
Description: Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
Study NCT00258856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide Diphtheria Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01713166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: plasmalyte solution
Description: plasmalyte solution
Study NCT01713166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hextend
Description: Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
Study NCT03692169 — intervention group
Intervention type: PROCEDURE
Intervention: Half-dose photodynamic therapy
Description: Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
Study NCT00859885 — intervention group
Intervention type: DRUG
Intervention: Antithrombotic treatment
Description: antiplatelets, anticoagulants
Study NCT00859885 — intervention group
Intervention type: DEVICE
Intervention: percutaneous device closure of PFO
Description: umbrella device for PFO closure
Study NCT04463927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-nutritive sucking
Description: intervention group received a sterile gloved finger during the examination for retinopathy of prematurity
Study NCT04545892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: One milliliter of each dilution was pipetted on to 2 cm filter paper squares. Then, the filter papers were let dry. Immediately before application, they were rehydrated with 1 milliliter of distilled water
Study NCT04114825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV001V
Description: RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
Study NCT04114825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
Study NCT03218475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR Guided Focused Ultrasound
Description: Two treatments of focused ultrasound under MRI guidance
Study NCT01589328 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative care integrated with usual oncologic care
Description: Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education
Study NCT01241240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)
Description: One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
Study NCT01241240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
Description: One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
Study NCT01212692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mentally stimulating activities
Description: The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
Study NCT01212692 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mentally stimulating activities
Description: The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
Study NCT01486329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Live anti-angiogenic cancer vaccine drink solution, escalating dose
Study NCT01486329 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink solution
Study NCT04319991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics product
Description: This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
Study NCT01110512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavonid
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day.
Study NCT01110512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daflon
Description: Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day
Study NCT01660373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: 0.4ug/kg/min for 30min followed by 0.1ug/kg/min
Study NCT01660373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: loading dose(180mg) followed by maintenance dose(90mg bid)
Study NCT03605550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTC596
Description: Oral tablets
Study NCT03605550 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Cycle1
Study NCT03523585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
Study NCT03523585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
Study NCT04319991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics product
Description: This Probiotics product is a supplement containing several types of probiotics and prebiotics which has been marketed for years in Taiwan. Each sachet contains 3 grams granule. Take 1 sticks 3 times per day with or without water before meals.
Study NCT03523585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Investigator's choice Standard of Care when combined with capecitabine
Study NCT03523585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Investigator's choice Standard of Care when combined with capecitabine
Study NCT04185870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D scan
Description: All participants will receive a 360 degrees 3D scan of their chest/pectus excavatum.
Study NCT00266032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
Study NCT00266032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
Study NCT00266032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)
Description: 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
Study NCT02977871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder flap
Description: Performing uterine incision and cesarean section with a bladder flap.
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK1562902A Formulation 1
Description: Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK1562902A Formulation 2
Description: Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine GSK1562902A Formulation 2
Description: Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study NCT01379937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix™ Junior
Description: Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
Study NCT04185870 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard photography
Description: All participants will receive a the standard photographs and specialised recordings of the current work-up to document their chest/pectus excavatum.
Study NCT02602899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PINS'Deep Brain Stimulator device
Description: deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Study NCT01550471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Study NCT00455767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-hNE4
Description: I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
Study NCT00455767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01134315 — intervention group
Intervention type: DRUG
Intervention: Paricalcitol
Study NCT01134315 — intervention group
Intervention type: DRUG
Intervention: Calcitriol
Study NCT04157621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active taVNS
Description: Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
Study NCT04157621 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.